Organization
Lee's Pharmaceutical Limited
8 clinical trials
Clinical trial
A Phase III, Randomized，Double-blind Placebo-controlled Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2023-10-13
Clinical trial
A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard TreatmentStatus: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Multicenter, Randomized, Double-blind, Controlled, Non-inferiority Phase III Clinical Trial of Recombinant Human Interferon Alpha-2b Gel (ZK-A03) in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient ManufacturerStatus: Not yet recruiting, Estimated PCD: 2023-07-30
Clinical trial
Phase III Clinical Trial Evaluating the Efficacy of 5-aminolevulinic Acid (5-ALA HCl) Fluorescence-guided Microsurgery Versus Conventional White Light Microsurgical Resection in Patients With Malignant Gliomas (WHO Grade 3/4)Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase Ⅲ, Efficacy and Safety Study of Intravaginal Prasterone (INTRAROSA) on Postmenopausal Vulvovaginal Atrophy (VVA)Status: Active (not recruiting), Estimated PCD: 2023-01-30
Clinical trial
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation RecipientsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcPStatus: Completed, Estimated PCD: 2023-03-15
Clinical trial
Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III StudyStatus: Not yet recruiting, Estimated PCD: 2027-09-01